Denavir

Denavir is a brand name of penciclovir topical, approved by the FDA in the following formulation(s):

DENAVIR (penciclovir sodium - cream; topical)

• 
  Manufacturer: DENCO ASSET
  
  Approval date: September 24, 1996
  
  Strength(s): 1% ^[RLD]

Has a generic version of Denavir been approved?

No. There is currently no therapeutically equivalent version of Denavir available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Denavir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Treatment of a latent infection of herpes viruses
  Patent 5,840,763
  Issued: November 24, 1998
  Inventor(s): Field; Hugh John & Thackray; Alana Maureen & Bacon; Teresa Helen & Sutton; David & Vere Hodge; Richard Anthony
  Assignee(s): SmithKline Beecham plc
  A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
  
  Patent expiration dates:
  
  
  • September 1, 2015
    
    ✓ 
    Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
  
  



• 
  Penciclovir for the treatment of post therapeutic neuralgia
  Patent 5,866,581
  Issued: February 2, 1999
  Inventor(s): Boon; Ronald James & Griffin; David Ronald John
  Assignee(s): SmithKline Beecham p.l.c.
  A method for the treatment of PHN in mammals, including humans, which method comprises administering an effective amount of a compound of formula (A), or a pharmaceutically acceptable salt thereof. ##STR1##
  
  Patent expiration dates:
  
  
  • October 4, 2014
    
    ✓ 
    Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
  
  



• 
  Treatment of a latent infection of herpes virus
  Patent 5,916,893
  Issued: June 29, 1999
  Inventor(s): Field; Hugh John & Thackray; Alana Maureen & Bacon; Teresa Helen & Sutton; David & Vere Hodge; Richard Anthony
  Assignee(s): SmithKline Beecham p.l.c.
  A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
  
  Patent expiration dates:
  
  
  • September 1, 2015
    
    ✓ 
    Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
  
  



• 
  Penciclovir for the treatment of zoster associated pain
  Patent 6,124,304
  Issued: September 26, 2000
  Inventor(s): Boon; Ronald James & Griffin; David Ronald John
  Assignee(s): SmithKline Beecham PLC
  A method for the treatment of ZAP, in particular PHN, in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof.
  
  Patent expiration dates:
  
  
  • October 4, 2014
    
    ✓ 
    Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
  
  



• 
  Pharmaceutical formulation
  Patent 6,469,015
  Issued: October 22, 2002
  Inventor(s): Hazel-Ann; Griffiths & Alan John; Goodall & Joshua; Oduro-Yeboah
  Assignee(s): Novartis International Pharmaceutical Ltd
  An oil-in-water topical pharmaceutical formulation or an aqueous formulation for the treatment of virus infections of the skin or mucosa, comprising at least 30% of propylene glycol and solubilized penciclovir.
  
  Patent expiration dates:
  
  
  • October 22, 2019
    
    ✓ 
    Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
  
  



• 
  Antiviral guanine derivatives
  Patent 6,579,981
  Issued: June 17, 2003
  Inventor(s): Richard Lewis; Jarvest & Michael Raymond; Harnden
  Assignee(s): Novartis International Pharmaceutical Ltd.
  A compound of formula (I) or a salt or acyl derivative thereof, in which X represents chlorine, C1-6 alkoxy, phenoxy, phenyl C1-6 alkoxy, NH2, —OH or —SH, is useful in treating viral infections.
  
  Patent expiration dates:
  
  
  • June 17, 2020
    
    ✓ 
    Patent use: TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
  
  

See also...

• Denavir Consumer Information (Drugs.com)
• Denavir Consumer Information (Wolters Kluwer)
• Denavir Consumer Information (Cerner Multum)
• Denavir Topical Advanced Consumer Information (Micromedex)
• Denavir AHFS DI Monographs (ASHP)
• Penciclovir Consumer Information (Wolters Kluwer)
• Penciclovir topical Consumer Information (Cerner Multum)
• Penciclovir Topical Advanced Consumer Information (Micromedex)
• Penciclovir AHFS DI Monographs (ASHP)